Metabolic Effects of Two Different Doses of Venlafaxine Therapy on Rats

1. Engl TJ, Laimer MS, et al. Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice, 2007;61:1356–1370.10.1111/j.1742-1241.2007.01416.x17627711Search in Google Scholar

2. Crandall JP, Knowler WC, Kahn SK, et al. The prevention of type 2 diabetes. Nature Reviews Endocrinology, 2008;4:382-393.10.1038/ncpendmet0843257304518493227Search in Google Scholar

3. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH - The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms, Expert Opinion on Drug Safety, 2006;5:157-168.10.1517/14740338.5.1.15716370964Search in Google Scholar

4. Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability, Prim Care Companion. J Clin Psychiatry, 2001;3:22–27.Search in Google Scholar

5. Masand PS, Gupta S. Long-Term side Effects of Newer-Generation Antidepressants: SSRIS, Venlafaxine, Nefazodone, Bupropion, and Mirtazapine. Annals of Clinical Psychiatry, 2002;14:175-182.10.3109/10401230209147454Search in Google Scholar

6. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the Dual Mechanisms of Action of Venlafaxine, Arch Gen Psychiatry, 2000;57:503-509.Search in Google Scholar

7. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmächer T.Search in Google Scholar

8. Body Weight, the Tumor Necrosis Factor System, and Leptin Production during Treatment with Mirtazapine or Venlafaxine. Pharmacopsychiatry, 2002;35:220-225.10.1055/s-2002-3639012518269Search in Google Scholar

9. Hummel J, Westphal S, Weber-Hamann B, Gilles M, et al. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. The Journal of Clinical Psychiatry, 2011;72:885-891.10.4088/JCP.09m05853blu21294998Search in Google Scholar

10. Khanam R, Najfi H, Akhtar M, Vohora D. Evaluation of venlafaxine on glucose homeostasis and oxidative stress in diabetic mice. Hum Exp Toxicol, 2012;31:1244-50.10.1177/096032711244684022751285Search in Google Scholar

11. Rosen ED, Sarraf P, Troy AE, et al. PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro, Molecular Cell, 1999;4:611–617.Search in Google Scholar

12. Wasan KM, Looije NA. Emerging Pharmacological Approaches to the Treatment of Obesity, J Pharm Pharmaceut Sci, 2005;8:259-271.Search in Google Scholar

13. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice, J Clin Invest, 2000;106:523–531.Search in Google Scholar